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Abstract
Introduction Endothelial damage accounts greatly for the high
mortality in septic shock. Higher expression of mediators (IL-6,
IL-8, soluble intercellular adhesion molecule 1 [sICAM-1],
soluble endothelial-linked adhesion molecule 1 [sELAM-1]) have
been described for non-survivors in comparison with survivors.
We investigated the predictive value of the mediators IL-6, IL-8,
sELAM-1 and sICAM-1 and their time course in intensive care
unit patients who developed septic shock with respect to
outcome.
Materials and methods We measured serum levels of IL-6, IL-
8, sELAM-1 and sICAM-1 in 40 intensive care unit patients who
developed septic shock. Measurements were performed until
death or until resolution of septic shock. Clinical and laboratory
data were also recorded.
Results After 48 hours the levels of sELAM-1 and sICAM-1
increased in non-survivors and decreased in survivors. sELAM-
1 was predictive for outcome on the third day (P = 0.02) and the
fourth day (P  = 0.02) after diagnosis of septic shock. This
difference in the time course between survivors and non-
survivors occurred 7 days before death of the patients (median,
10 days). sICAM-1 levels increased significantly in non-survivors
over the study period (P < 0.001). sELAM-1 (P = 0.04), IL-6 (P
= 0.04) and IL-8 (P = 0.008) were significantly higher in non-
survivors over the whole study period. The age and
norepinephrine dose >0.5 µg/kg/min were significantly different
between the groups.
Conclusion sELAM-1 showed a markedly opposing course
after 48 hours of septic shock. This adhesion molecule may be
a useful early predictor of disease severity in the course of septic
shock after early initial treatment of the patients, and might
suggest considering endothelial-restoring therapy.
Introduction
Endothelial damage accounts for much of the pathology of
sepsis, resulting in capillary leak, hypotension, microvascular
thrombosis with consecutive tissue hypoxia and, finally, multi-
ple organ failure (MOF) and lethal outcome [1-3]. Endothelial
damage is worsened in septic shock [4]. The mortality of sep-
tic shock is higher than the mortality in sepsis (35–60% versus
20–40%) [4,5]. The release of cytokines (IL-6, IL-8) and adhe-
sion molecules (soluble endothelial-linked adhesion molecule
1 [sELAM-1], soluble intercellular adhesion molecule 1
[sICAM-1]) has been shown to correlate well with endothelial
damage in an experimental setting – especially for sELAM-I,
which is specific for endothelial tissue [2,6,7]. Although the
release of these mediators is not only sepsis related, the levels
are significantly higher in sepsis and in septic shock than after
trauma, postoperatively or after myocardial infarction [8-12]. In
addition, these mediators have higher levels in non-survivors
than in survivors, and the baseline levels have been correlated
with outcome [2,3,8,10-15].
The time of admission to the study and the onset of therapy are
of major relevance for outcome, however, as shown by Rivers
and colleagues in the early goal-directed therapy study in
severe sepsis and septic shock patients [16]. As early clinical
intervention improves outcome and as there are increasing lev-
els of cytokines in non-survivors, in comparison with a
AUC = area under the receiver operating characteristics curve; ECG = electrocardiogram; ICU = intensive care unit; IL = interleukin; MOF = multiple 
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decrease in survivors, differences in the mediator time course
between survivors and non-survivors after early onset of ther-
apy could be predictive for the outcome and for trend-setting
for further therapy measures [10,11,15,17-19].
We investigated the predictive value of the mediators IL-6, IL-
8, sELAM-1 and sICAM-1 and their time course, as primary
outcome measures, in intensive care unit (ICU) patients who
developed septic shock with respect to outcome. In addition,
IL-8 as an early chemoattractant cytokine and IL-6 as an
inflammatory tissue damage marker were investigated. Clinical
data, such as age, the use of hemodynamically active sub-
stances and myocardial ischemia, were investigated as sec-
ondary outcome measures.
Materials and methods
Patients
After ethical committee approval and written informed consent
from the legal representatives, 42 patients suffering from sep-
tic shock were enrolled in this observational study. Two
patients had to be excluded after enrollment because of immi-
nent surgery, so 40 patients completed the study. All patients
fulfilled the clinical and laboratory criteria of septic shock as
outlined in the 1992 Consensus Conference [20]. Exclusion
criteria were age <18 years, pregnancy, patients who have
had surgery within 48 hours before inclusion and patients who
have had cardiac surgery and neurosurgery. Patients with an
acute history of severe cardiac insufficiency (New York Heart
Association class III-IV) [21] and coronary artery disease
before the development of septic shock were also excluded
[22].
Monitoring and management
The study was initiated in the first 24 hours after septic shock
had been diagnosed. All patients were already admitted to the
ICU and were under ICU standard therapy and monitoring
[23]. All patients received analgesia, sedation and mechanical
ventilation. The patients were screened twice a day. The study
ended in the case of death or in resolution of septic shock.
A fiber optic pulmonary artery flotation catheter (Baxter Swan-
Ganz® Intelicath™ continuous cardiac output thermodilution
catheter 139H, 7.5 Fr; Baxter/Edwards Critical-Care, Irvine,
CA, USA) and a radial artery catheter were inserted as part of
the routine for continuous cardiovascular monitoring in septic
shock. Hemodynamic measurements were recorded at study
entry and every 8 hours during the study. Fluids were given to
achieve an optimal left atrial pressure. After adequate fluid
resuscitation, norepinephrine (maximum 4.0 µg/kg/min) was
titrated to maintain a mean arterial pressure >70 mmHg. Cat-
echolamine therapy in the case of low-output failure was per-
formed primarily with dobutamine (maximum 20 µg/kg/min) or
dopamine (maximum 10 µg/kg/min) at the discretion of the
physician on duty. Enoximone (maximum 10 µg/kg/min) was
added if low-output failure persisted, and then epinephrine
infusion (maximum 2.0 µg/kg/min) was initiated if low-output
failure remained. The target value was a cardiac index >3.0 l/
min/m2. The amount of different positive inotropic substances
was expressed as the number used in each group.
A 12-lead Holter electrocardiogram (ECG) was recorded
every 8 hours to determine possible myocardial ischemia,
defined by Spies and colleagues [22]. The oxygenation index
was calculated as the quotient of partial arterial oxygen pres-
sure and the inspired oxygen fraction (mmHg).
Group assignment
It was decided a priori to assign patients to the survivors group
when they were discharged from the ICU to a regular ward.
Those patients who died due to septic shock were assigned
to the non-survivors group. Patients who died from a cause
other than septic shock and consecutive MOF during their ICU
stay were excluded from the study.
Laboratory data
Blood gas analysis was performed every 8 hours to determine
the levels of hematrocrit and hemoglobin, and the arterial par-
tial oxygen pressure (ABL 500; Radiometer, Copenhagen,
Denmark).
Creatin kinase and the creatin kinase-myocardial bands were
determined every 8 hours (BM/Hitachi 717 analyser; Boe-
hringer Mannhein, Inc., Mannheim, Germany). The creatin
kinase/creatin kinase-myocardial band fraction was calculated
and a result >6% was recorded positive for myocardial
ischemia [22]. Blood samples for the determination of IL-6
concentrations (Enzymeimmunoassay [Milenia®]; DPC Bier-
mann GmbH, Bad Nauheim, Germany), of IL-8 concentrations
(Enzymeimmunoassay [Milenia®]; DPC Biermann GmbH), of
sICAM-1 concentrations (enzyme immunoassay kit BBE 1b;
R&D Systems, Minneapolis, MN, USA), of sELAM-1 concen-
trations (enzyme immunoassay kit BBE 2b; R&D Systems) and
of troponin T concentrations (enzyme-linked immunosorbent
assay Enzymun-Test™ batch ELISA ES 300 analyser; Boe-
hringer Mannheim Inc.) were withdrawn every 8 hours and
were centrifuged, and the plasma was stored at -80°C until
analysis.
Statistical analysis
Data are expressed as the median and range. Intergroup sta-
tistical analysis for determined time intervals was performed
using the Mann–Whitney U test for continuous variables and
using the Pearson chi-square test for dichotomous variables.
Intragroup statistical analysis for the determined time intervals
was performed with the Wilcoxon matched-pairs signed-rank
sum test. For intergroup and intragroup analysis over the
whole study period, the two-factorial non-parametric (analysis
of variance)-type rank variance analysis for longitudinal data
and small sample sizes using the SAS System software (SAS
Institute Inc., Cary, NC, USA) was used. Variables that wereAvailable online http://ccforum.com/content/9/4/R323
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significantly different between groups were analysed as pre-
dictors for outcome (group variable, survivor/non-survivor),
determining the area under the receiver operating characteris-
tics curve (AUC). The AUC, the P value and the 95% confi-
dence intervals are stated. P  < 0.05 was considered
statistically significant.
Results
Forty patients were included in the study and 16 (40%)
patients were discharged from the ICU to a normal ward.
Twenty-four (60%) patients died due to septic shock. Patients
in the non-survivor group were significantly older and stayed a
significantly shorter time in the ICU than the survivors (Table
1). Survivors had a significantly higher rate of pneumonia as
the sepsis focus whereas non-survivors had a significantly
higher rate of peritonitis as the focus (Table 1). The Acute
Physiology and Chronic Health Evaluation III baseline score
and the Acute Physiology and Chronic Health Evaluation III
maximum score did not significantly differ between the groups
(Table 1). All patients required norepinephrine therapy but sig-
nificantly more non-survivors than survivors required nore-
phinephrine infusion >0.5 µg/kg/min (Table 2). The number of
positive inotropic agents necessary and the markers for myo-
cardial ischemia (monitored by ECG), for creatin kinase/crea-
tin kinase-myocardial band fraction >6% and for troponin T
were not significantly different between survivors and non-sur-
vivors (Table 2).
Intergroup analysis of variance between survivors and non-sur-
vivors showed significantly higher levels for IL-6 (P = 0.04), for
IL-8 (P = 0.008) and for sELAM-1 (P = 0.04) in the non-survi-
vors group. sICAM-1 (P = 0.25) was not significantly higher in
levels in the non-survivors group. The intragroup analysis for
IL-6 showed a significant decline between the first value and
the last value (before discharge from the study or death) for
survivors (P = 0.002) and non-survivors (P = 0.04) (Fig. 1).
The intragroup analysis for IL-8 between the first value and the
last value (before discharge from the study or death) was not
significantly different in both groups (survivors, P = 0.17; non-
survivors, P = 0.78) (Fig. 2).
After a comparable course in the first 2 days, non-survivors
showed an increase in median values of sELAM-1 and sICAM-
1 whereas survivors' adhesion molecule levels decreased
markedly (Figs 3 and 4). This increase was significant for
sICAM-1 in the non-survivor group when comparing the first
value with last value before discharge from the study or death
of the patients (P < 0.001) (Fig. 4). The marked decline of
median values for sELAM-1 in the survivor group was signifi-
cant in the comparison of the first time point with the last time
point before discharge from the study or death (P = 0.04) (Fig.
3). When comparing survivors and non-survivors at single time
points, sELAM-1 was significantly higher in non-survivors from
the third day onwards (P = 0.02) (Fig. 3).
The AUC values for baseline, the third day and the fourth day
measurements of IL-6, IL-8, sELAM-1 and sICAM-1 are pre-
sented in Table 3. IL-8 was most predictive for outcome at
baseline, and sELAM-1 most predictive on the third and fourth
days (Table 3). The AUC for age (AUC, 0.761; P = 0.01; 95%
Table 1
Baseline and outcome data
Survivors (n = 16, 40%) Non-survivors (n = 24, 60%) P*
Age (years) 59 (28–82) 65 (33–86) 0.03
Sex (male/female) 11/5 11/13 0.15
Intensive care unit stay (days) 27 (11–48) 8 (2–57) <0.01
Sepsis focus (n)
Pneumonia 9 4 0.02
Peritonitis 2 13 0.04
Wound infection 3 4 >0.99
Abscess 2 3 >0.99
Hemoglobin (g/dl) 10 (7–14) 11 (7–13) 0.61
Oxygenation index (mmHg) 245 (114–421) 199 (89–384) 0.44
APACHE III baseline score 55 (23–88) 61 (12–100) 0.91
APACHE III maximum score 75 (52–108) 86 (52–117) 0.47
MODS baseline 6 (2–11) 7 (2–12) 0.36
MODS max 9 (5–15) 9 (4–14) 0.73
Data presented as median (range). APACHE, Acute Physiology and Chronic Health Evaluation; MODS, multiple organ dysfunction syndrome.
*P value for intergroup baseline and outcome data: Mann–Whitney U test, and Pearson chi-square and Fisher exact tests, respectively.Critical Care    Vol 9 No 4    Hein et al.
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confidence interval, 0.624–0.898) and that for median nore-
pinephrine dosage (AUC, 0.766; P = 0.001; 95% confidence
interval, 0.636–0.896) were also significantly predictive for
outcome.
Discussion
The most important finding in this study was the different time
courses of the markers of endothelial damage (sELAM-1 and
sICAM-1) after the second day in survivors and non-survivors
of septic shock. After a comparable course at different levels
in the first 2 days, non-survivors had an increase in adhesion
molecule concentrations whereas survivors' adhesion mole-
cule levels decreased markedly. SELAM-1 was predictive for
outcome on the third and fourth days after the diagnosis of
septic shock. This difference in time courses between survi-
vors and non-survivors was evident on the third day and, there-
fore, far before death of the patients (median, 10 days).
Endothelial damage accounts for much of the pathology of
septic shock, resulting finally in MOF and lethal outcome [1-3].
sELAM-1 is specific for endothelial tissue [2,7]. The latter
marker and sICAM-1 have been shown to be significantly ele-
vated at baseline and inconsistent in levels over the whole
study period in sepsis, in comparison with trauma patients or
critically ill patients without sepsis [2,3,8-12]. The levels of
adhesion molecules in septic shock patients have been
described as markedly elevated at baseline in comparison with
septic patients without shock [10,12,24]. In addition, sELAM-
1 and sICAM-1 have been shown to be markedly elevated at
Table 2
Clinical and laboratory data
Survivors (n = 16, 40%) Non-survivors (n = 24, 60%) P*
Norepinephrine (n) 16 (100%) 24 (100%)
Norepinephrine >0.5 µg/kg/min mean values (n)8 2 2 < 0 . 0 1
Number of + inotropic medications (dobutamine or 
dopamine, enoximone and epinephrine) (n)
0.79
03 6
19 1 1
24 6
30 1
Myocardial ischemia signs in electrocardiogram (n)1 2 1 5 0 . 4 1
Troponin T >0.2 (ng/ml) 5 7 0.89
CK/CK-MB fraction >6% 1 0 0.22
Data presented as median (range). CK/CK-MB, creatin kinase/creatin kinase-myoglobin band.
*P value for intergroup data analysis: Pearson chi-square and Fisher exact tests.
Figure 1
IL-6 for survivors and non-survivors over time IL-6 for survivors and non-survivors over time.
Figure 2
IL-8 for survivors and non-survivors over time IL-8 for survivors and non-survivors over time.Available online http://ccforum.com/content/9/4/R323
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baseline in non-survivors in comparison with survivors, as
shown in the present study [2,8,10-12,24].
In the present study, non-survivors (in comparison with survi-
vors) showed elevated adhesion molecule levels over the
whole study period. After a comparable time course at differ-
ent levels over the first 48 hours, the endothelial mediator lev-
els increased in non-survivors and decreased in survivors.
Table 3
Predictive parameters determined by the area under the receiver operating characteristics curve (AUC)
Time point AUC 95% confidence interval P
Baseline
IL-8 0.777 0.619–0.935 0.004
IL-6 0.648 0.462–0.834 0.14
sELAM-1 0.600 0.400–0.800 0.30
sICAM-1 0.548 0.360–0.735 0.622
Third day
IL-8 0.133 0.402–0.923 0.25
IL-6 0.727 0.501–0.953 0.087
sELAM-1 0.808 0.599–1.017 0.02
sICAM-1 0.677 0.427–0.927 0.18
Fourth day
IL-8 0.775 0.529–1.021 0.05
IL-6 0.737 0.504–0.971 0.09
sELAM-1 0.847 0.631–1.064 0.02
sICAM-1 0.694 0.433–0.956 0.18
sELAM-1, soluble endothelial-linked adhesion molecule 1; sICAM-1, soluble intercellular adhesion molecule 1.
Figure 3
Soluble endothelial-linked adhesion molecule 1 (sELAM-1) for survivors  and non-survivors over time Soluble endothelial-linked adhesion molecule 1 (sELAM-1) for survivors 
and non-survivors over time. * Significant difference (P < 0.05) for 
sELAM-1 between survivors and non-survivors.
Figure 4
Soluble intercellular adhesion molecule 1 (sICAM-1) for survivors and  non-survivors over time Soluble intercellular adhesion molecule 1 (sICAM-1) for survivors and 
non-survivors over time.Critical Care    Vol 9 No 4    Hein et al.
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sELAM-1 was predictive for outcome at the third and fourth
days. Kayal and colleagues investigated patients with severe
sepsis (56%) and with septic shock (44%) on admission to
the ICU or during ICU hospitalisation. Seventy-two percent of
the septic shock patients had a putative sepsis onset >6 hours
before inclusion in the study, and 82% of the septic shock
patients died after a median time of 3 days [10]. Fifty percent
of the severe sepsis patients had a putative sepsis onset >6
hours before inclusion into the study, 14% of which died after
6 days in the ICU [10]. Kayal and colleagues observed an
increase in sICAM-1 and sELAM-1 levels for 3–4 days after
study inclusion in non-survivors, sELAM-1 then returning to
levels similar to those observed in survivors whereas sICAM-1
continued to increase in non-survivors [10]. Those authors
concluded that baseline sICAM-1 and sELAM-1, as markers of
endothelial cell activation, predicted disease severity – and
sICAM-1 more then sELAM-1 reflected the intensity of inflam-
mation and tissue damage in late sepsis [10].
Boldt and colleagues investigated septic patients already
admitted to the ICU at the onset of sepsis, 40% of which died
[11]. The authors also demonstrated that sELAM-1 decreased
over time in septic patients while sICAM-1 increased further
[11]. Cowley and colleagues investigated adhesion molecule
levels of patients admitted to the ward or the ICU within 12
hours after the onset of systemic inflammatory response syn-
drome, with or without signs of organ dysfunction or hypoper-
fusion – 60% of them died [18]. This study group observed
increased levels of sELAM-1 over the study period in patients
with sustained organ dysfunction and in non-survivors,
whereas sELAM-1 levels decreased in patients whose organ
dysfunction resolved [18]. Sessler and colleagues measured
sICAM-1 levels of septic patients (64% in septic shock, from
which 75% died) within 12 hours after admission to the ICU
for sepsis, of which 48% died [12]. The authors were able to
show that baseline sICAM-1 levels correlate independently
with outcome [12]. Cummings and colleagues investigated
sELAM-1 levels within 24 hours of admission to the ICU of
119 critically ill patients (7% had no systemic inflammatory
response syndrome, 37% had non-infectious systemic inflam-
matory response syndrome, 56% were septic, 34% were in
shock) [24]. The authors found a modest correlation between
day 1 sELAM-1 levels and organ dysfunction as well as sur-
vival [24].
The inclusion time of patients into the study could be crucial
for the course and interpretation of mediator levels in relation
to outcome [17]. If admission and therapy is delayed, mediator
levels might already be high at admission [17]. The clinical
signs of septic shock become evident when the inflammatory
insult is already ongoing and initialising therapy might be
delayed, leading to a worse outcome [16]. The early goal-
directed therapy performed by Rivers and colleagues in septic
shock patients provided a significant outcome benefit [16].
Our patients, who were already under standardised ICU ther-
apy before septic shock began, died 7 days (median) after
possible outcome prediction by enhanced endothelial damage
markers in non-survivors. The monitoring of sELAM-1 and
sICAM-1 over the time course of septic shock could probably
indicate when the patients' course is leading to lethal outcome
and could help physicians to intervene and monitor further
therapy before the patients die. Such therapies aim at recruit-
ing the endothelium; for example, the application of activated
protein C.
IL-6 has been described to have pro-inflammatory and anti-
inflammatory properties in different animal and human septic
and non-septic models [2,15,25,26]. IL-6 is widely accepted
as a marker for disease severity in septic shock but elevations
are not sepsis specific [13,15,27-29]. However, as has been
demonstrated for adhesion molecules, IL-6 levels in septic
shock patients were significantly higher and stayed higher in
non-survivors than in survivors, as shown in the present study
[13-15,17,27,28]. The predictive value of IL-6 on admission
has been described for septic patients and septic shock
patients [14,15,19]. Baseline values in our study were not pre-
dictive for outcome, perhaps because of the early entry time
into the study as described earlier.
IL-6 tended to correlate with outcome on the third and fourth
days after onset of septic shock. Pinsky and colleagues
described the persistence of high levels of IL-6, and not the
peaks of IL-6, as being predictive for outcome [17]. IL-6 con-
tinuously dropped in survivors whereas it showed a variable
course in non-survivors. This variability has been described in
patients suffering from sepsis and from septic shock [13,15].
In both groups, however, IL-6 levels decreased significantly
from admission until the end of this study, in contrast to other
cytokines such as tumor necrosis factor alpha or to other
adhesion molecules, as shown in other studies and our own
[14,15]. Presterl and colleagues observed a steady decrease
in IL-6 over a 7-day period in survivors and observed persistent
high levels in non-survivors [13]. This course could be related
to an initial pro-inflammatory characteristic and a later anti-
inflammatory characteristic of IL-6 when compared with the
explicit pro-inflammatory cytokine tumor necrosis factor alpha
[14,15,25,26].
IL-8 was significantly higher in non-survivors than in survivors,
and it was predictive for lethal outcome at baseline. IL-8, a
chemoattractant, is an early pro-inflammatory component
released in sepsis by endothelial cells and other cells [7]. High
levels of IL-8 have been described in sepsis, in shock and in
MOF with poor outcome, consistent with our study [29-31].
These results, however, are conflicting in the literature
[29,31,32]. Especially for early detection of nosocomial pneu-
monias and newborn infections, IL-8 has been shown to be an
adequate marker and predictor [33-36]. The predictive value
of this parameter at baseline, as shown in the present study,Available online http://ccforum.com/content/9/4/R323
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might be a hint that patients were in the phase of early septic
progression.
The rate of pneumonias and peritonitis as the septic focus was
significantly different between survivors and non-survivors.
After revision of the literature, no data could be found regard-
ing possible differences in expression of endothelial damage
markers and outcome looking at different infection sites.
All our patients required norepinephrine therapy. Significantly
more non-survivors needed norepinephrine at a dose >0.5 µg/
kg/min than survivors, probably due to profound volume-
refractory vasodilation. Norepinephrine follows dopamine as
the first-choice vasopressor in septic shock and has been
applied in dosages as high as 5 µg/kg/min [4,37]. The use of
positive inotropic therapy to achieve supramaximal hemody-
namic values for oxygen delivery, for mixed venous oxygen sat-
uration and for cardiac index has been reported to worsen the
outcome of patients in septic shock [38-40]. In the present
study the use of positive inotropic therapy did not differ
between survivors and non-survivors. Although myocardial
dysfunction has been extensively described in sepsis, the main
pathophysiology developing in septic shock is the peripheral
vasodilation with consecutive hypotension [4,37,41,42]. As
myocardial dysfunction/ischemia may be contributing factors
influencing study results and the outcome, patients with an
acute history of severe cardiac insufficiency and coronary
artery disease before the development of septic shock were
excluded from the study. The laboratory parameters for myo-
cardial ischemia and the ECGs performed did not show differ-
ences in signs of myocardial ischemia between survivors and
non-survivors. The high incidence of myocardial ischemic
signs observed in the ECGs has to be interpreted carefully.
Other studies have described the low specificity of ECG in
comparison with troponin T for the diagnosis of myocardial
ischemia [8].
Patients in the non-survivor group in this study were signifi-
cantly older than the survivors. Age was also a significant pre-
dictor of lethal outcome in the AUC analysis. The patients' age
has been described as a risk factor of fatal outcome in patients
with sepsis, explained by a possibly diminished physiologic
reserve and a poor immune status [1,5,19,43]. Boldt and col-
leagues were able to show higher levels of sELAM-1 and
sICAM-1 in patients older than 70 years in comparison with
patients younger than 50 years, indicating an association with
more extensive endothelial damage [43]. In the present study,
sELAM-1 was significantly higher in patients older than 65
years (P  = 0.01). When excluding non-survivors, however,
sELAM-1 was no longer significantly higher in patients older
than 65 years (P = 0.60).
A major limitation of the present study is the low number of
patients. This fact could be the cause for the large range in
standard deviation of the markers measured. A far greater
number of patients will be needed to verify the results
presented.
Conclusion
The endothelial marker sELAM-I showed a markedly opposing
and predictive course after 48 hours of septic shock. Our data
suggest that the adhesion molecule sELAM-1 might be useful
in assessing disease severity in the course of septic shock
after early initiation of treatment. This might provide a valuable
means of monitoring and a means of guidance of therapy with
substances known to reduce endothelial damage (such as, for
example, activated protein C).
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